{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-26-000026","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.599805+00:00","generated_at":"2026-05-15T13:25:02.795137+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elicio Therapeutics reports FY2025 net loss of $39.5M; Phase 2 PDAC trial DFS readout expected 1H 2026","bullets":["Net loss for 2025 was $39.5M ($2.58 per share), compared to $51.9M ($4.25) in 2024.","R&D expense decreased to $24.9M from $33.7M; G&A expense increased to $12.8M from $11.3M.","Cash and equivalents $18.6M as of Dec 31, 2025; runway into Q3 2026 beyond expected Phase 2 DFS analysis.","Phase 2 AMPLIFY-7P trial in PDAC: fewer progressions and deaths observed than projected; primary DFS analysis on track for 1H 2026.","Raised net ~$4.9M in Q4 2025 and ~$6.3M in Q1 2026 via at-the-market program; appointed Marc J. Wolfgang as CTO."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-26-000026","json":"https://secwatch.observer/filing/0001601485-26-000026.json","markdown":"https://secwatch.observer/filing/0001601485-26-000026.md","text":"https://secwatch.observer/filing/0001601485-26-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/0001601485-26-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/angn-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:25:02.795137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61fb6829a5eedd1f01502d7e0b08f1261eb176b8","claim":"Elicio Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $39.5 million, EPS $2.58.","evidence_excerpt":"Net loss for 2025 was $39.5 million, compared to $51.9 million for 2024. Net loss for 2025 includes $1.9 million of non-cash other expense resulting from the change in fair value of the warrant liability. Net loss per share for 2025 was $2.58, compared to $4.25 for 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/0001601485-26-000026-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"$39.5 million"},{"label":"EPS","value":"$2.58"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}